Skip to main content
. 2019 Jul 25;4(14):e125652. doi: 10.1172/jci.insight.125652

Figure 5. Intravenous administration of m–iPSC-EVs reduces development of fibrosis and HSC activation in an experimental model of cholestatic liver fibrosis.

Figure 5

(A) Representative microphotographs and (B) corresponding quantification graph of Picrosirius red staining of liver sections harvested from mice that received common bile duct ligation (BDL) for 2 weeks (n = 5–6 mice/group) and were administered, by tail vein, mouse iPSC-EVs (BDL iPSC-EVs) or vehicle control (BDL vehicle) for the last 6 days of the study. Mice that underwent abdomen laparotomy but did not receive BDL were used as no-disease controls (sham). Original magnification, ×10. (C) Immunoblots and (D) corresponding quantification graph of αSMA protein levels over 2 weeks in BDL mice treated with mouse iPSC-EVs or with vehicle for the last 6 days of the study. Tubulin was used as a loading control for Western blots. Values represent mean ± SD. *P < 0.05, and **P < 0.005; Kruskal-Wallis test with post hoc Mann-Whitney test and Bonferroni’s correction were used for statistical analysis.